Scienza e Tecnologia
CP-COV03, a niclosamide-based oral antiviral drug, under study as possible cure for COVID-19 variants
At a press conference held at the Korea Press Center on the 7 , Hyundai Bioscience announced the results of these experiments and decided to provide related data to the medical community. This is the first study result that confirmed the synergistic effect of an oral antiviral drug with dexamethasone as COVID-19 combo treatment.
CP-COV03 is a broad-spectrum antiviral drug candidate, developed by Hyundai Bioscience to treat COVID-19. Its active pharmaceutical ingredient is niclosamide, an anthelmintic drug, and is expected to work on various viral diseases including COVID-19 and its mutations as well as influenza.
CP-COV03 was originally developed with the advanced drug delivery system (DDS) technology by CNPharm, a major shareholder of Hyundai Bioscience. It is a 'host-directed' drug that focuses on the host cell, unlike existing vaccines and antiviral drugs that target the virus. Niclosamide received international attention after COVID-19 broke out, since its efficacy against mutations of COVID-19 has been proven through multiple researches.
Hyundai Bioscience, emphasizing on multi-target capability of niclosamide that may cure COVID-19 variants, plans to expand the use of CP-COV03 to treat even other viral diseases such as the flu.
If successfully approved, CP-COV03 is expected to be a game-changer drug in the war against virus of the century as it is inexpensive and easy to mass-produce. It can be administered to patients with dual or multiple viral diseases such as COVID-19 and influenza at an affordable price.
Photo - https://mma.prnewswire.com/media/1704190/Hyundai_Bioscience.jpg
Logo - https://mma.prnewswire.com/media/1704302/Logo.jpg